Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUWHY
2023-508314-42-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Feb 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of durvalumab and tiragolumab in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Started Feb 2020; status: completed.
02
Drugs
durvalumabtiragolumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2023-508314-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508314-42-00.